158 related articles for article (PubMed ID: 4048979)
1. Pharmacologic reversal of drug resistance in ovarian cancer.
Ozols RF
Semin Oncol; 1985 Sep; 12(3 Suppl 4):7-11. PubMed ID: 4048979
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
[No Abstract] [Full Text] [Related]
3. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
[TBL] [Abstract][Full Text] [Related]
4. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
7. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance in ovarian cancer.
Fojo A; Hamilton TC; Young RC; Ozols RF
Cancer; 1987 Oct; 60(8 Suppl):2075-80. PubMed ID: 3308067
[TBL] [Abstract][Full Text] [Related]
9. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
[TBL] [Abstract][Full Text] [Related]
10. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
12. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.
Hamilton TC; Young RC; Ozols RF
Semin Oncol; 1984 Sep; 11(3):285-98. PubMed ID: 6385258
[No Abstract] [Full Text] [Related]
13. The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin.
Mutch DG; Herzog TJ; Chen CA; Collins JL
Gynecol Oncol; 1992 Oct; 47(1):28-33. PubMed ID: 1427396
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
Ozols RF; Masuda H; Hamilton TC
NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
18. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
[TBL] [Abstract][Full Text] [Related]
19. Reversal of adriamycin resistance by verapamil in human ovarian cancer.
Rogan AM; Hamilton TC; Young RC; Klecker RW; Ozols RF
Science; 1984 Jun; 224(4652):994-6. PubMed ID: 6372095
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
